Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 81

recruiting
3 972
countries
28
conditions
2 103

1 070 trials match your criteria

Small cell lung cancer extensive stage

Not recruiting

Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Neoplasm malignant+2

Not recruiting

Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Larotrectinib Sulfate

Cervix carcinoma

Not recruiting

Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate

Colorectal cancer metastatic

Not recruiting

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Methylprednisolone

Type 1 diabetes mellitus

Not recruiting

Study on Frexalimab for Preserving Insulin Production in Newly Diagnosed Type 1 Diabetes Patients Aged 12-21 on Insulin Therapy

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years

Adenocarcinoma pancreas

Not recruiting

Study on the Effectiveness and Safety of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX in Patients with Resected Pancreatic Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide

Retinitis pigmentosa

Not recruiting

Study on the Safety and Effects of CPK850 Gene Therapy for Patients with Retinitis Pigmentosa Due to RLBP1 Gene Mutations

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:CPK850

Neoplasm malignant+1

Not recruiting

Study on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Larotrectinib Sulfate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.